On March 31, 2020, Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gene therapies (CGTs), announced that it has developed a breakthrough and patented manufacturing process for Bioxomes™ (synthetic exosomes/extracellular vesicles), through its collaboration and licensing agreement with Excella-Bio Ltd. Exosomes, or extracellular vesicles (EVs), are small vesicles that can transfer DNA, RNA, and proteins from the cell of origin to other, often targeted cells, thereby enabling alteration of the function of the targeted cells. It is belieed that exosomes can provide the same therapeutic benefit of whole cells, without the risks and difficulties of administering entire cells to patients. Together, Orgenesis and Excella-Bio have developed Bioxomes, which are synthetic exosomes/EVs. Until now, exosome/EV production has been based on conventional ultracentrifugation or ultrafiltration. These are both complex and costly techniques. Bioxomes are engineered and produced through a patented method as membrane nanoparticles isolated from cell cultures of various sources. Orgenesis and ExcellaBio have now demonstrated the optimization and scale-up of Bioxomes™, while generating consistent and repeatable results, including uniform particles sizes. These Bioxomes have demonstrated the ability to fuse with cell membranes and deliver an intracellular cargo, in a similar manner to that of natural exosomes. Bioxomes can be sourced effectively from various cell cultures. These include mesenchymal stem cells, immortalized cells, immune cells, and epithelial cells.
Login Or Register To Read Full Story